In the BOREAS and NOTUS trials, Dupixent cut the rate of exacerbations by 30% and 34%, respectively, and both those studies specifically enrolled patients with BEC levels of 300 cells/μL or above.

The lung disease affects more than 300 million people globally ... Sanofi and Regeneron's big-selling IL-4 and IL-13 inhibitor Dupixent (dupilumab) as a treatment for the progressive lung disease ...

Celldex has a strong cash position with a runway of 13-14 quarters, bolstered by a $424 million secondary offering in March 2024. Learn more on CLDX stock here.

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Where Honda’s CRF300 Rally is the class-leader for rally-style trailies, it finally has some competition from Chinese brand Voge and their Rally 300. For those of you who haven’t heard of Voge ...

Bristol Myers Squibb has continued its ruthless cost-cutting push, dropping plans to commercialize a rival to Dupixent despite meeting its phase 3 goals and pumping the brakes on a would-be ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent—including agreements with payers and pharmacy benefit managers that ...

This is how biologic treatments can help. Dupixent (dupilumab) was the first biologic treatment approved for atopic dermatitis. It became available in 2017. It is currently approved for adults, ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Pre-Market: 6:59:59 a.m. EST ...

The Royal Enfield Bullet 350 holds a special place in the segment due to its retro design, rich heritage, and reliability. The Bullet 350 is built on an all-new chassis to contain RE's new J ...